Nano-X Imaging (NNOX) Q1 2026: Revenue Miss, Going Concern Warning
As seen on the 24/7 Wall St. homepage on June 25, 2026.
Nano-X Imaging crushed expectations on the downside with a 30% revenue miss and a going concern warning, prompting the company to ditch its 2026 guidance and halt periodic financial targets entirely. The medical imaging company burned $13.95 million in operating cash last quarter while cash reserves fell to just $44.2 million, leaving it racing against a shrinking runway to land its Nanox.ARC deployments and fix its commercialization timeline.
Continue ReadingShow less
Nano-X Imaging reported a loss of $0.16 per share for Q1 2026, missing the consensus estimate of $0.14 by about 14%. The revenue picture was considerably worse: the company brought in just $4.31 million against expectations of $6.12 million, a shortfall of roughly 30%. On the back of those results, management pulled its full-year 2026 guidance and said it would stop issuing periodic financial targets altogether.
The cash position is what makes this report particularly pressing for investors. Nano-X burned through $13.95 million in operating cash during the quarter, and its reserves have fallen to $44.2 million. The company disclosed a going concern warning, meaning its auditors have flagged doubt about its ability to continue operating without additional funding or a meaningful acceleration in revenue. The shrinking runway puts significant pressure on the company to get its Nanox.ARC devices deployed and generating consistent income.
Sponsored
Are You Ready To Retire, Or Years Behind?
Most Americans suspect they're behind on retirement and never find out. Advisor.com's free matching tool pairs you in about three minutes with a vetted fiduciary advisor who can help you with investing, taxes, retirement, estate planning, and more. No minimums. No sales call. Find out where you stand.
The key things to watch from here are the pace of Nanox.ARC deployments, any announcements around financing or cost-cutting, and whether the company can stabilize its commercialization timeline before cash runs critically low. With guidance scrapped and no new financial targets on offer, investors have little from management to anchor expectations going forward.
Mentioned: NNOX